TABLE 3.
Long-term efficacy of HDPC against established L. infantum infection in BALB/c micea
| Treatment group | Day of evaluation | Body wt (g) | Relative wt (%)b
|
% Efficacyc
|
||
|---|---|---|---|---|---|---|
| Liver | Spleen | Liver | Spleen | |||
| HDPC | D42 | 23.2 ± 1.0 | 4.7 ± 0.6 | 0.5 ± 0.1 | 98.9 | 98.8 |
| D63 | 22.4 ± 0.7 | 5.6 ± 0.4 | 0.6 ± 0.1 | 90.4 | 91.8 | |
| D84 | 25.4 ± 0.6 | 4.9 ± 0.4 | 0.6 ± 0.1 | 92.5 | 88.8 | |
| NTC | D42 | 23.5 ± 1.0 | 5.2 ± 0.4 | 0.8 ± 0.2 | ||
| D63 | 22.1 ± 0.7 | 6.1 ± 0.4 | 1.3 ± 0.3 | |||
| D84 | 25.0 ± 0.5 | 5.4 ± 0.5 | 2.0 ± 0.4 | |||
a
Mice, intravenously inoculated with 108 stationary-phase L. infantum promastigotes/mouse on D0 and treated for 5 days (starting D28) with HDPC (20 mg/kg of body weight/day, oral administration) or left untreated, were examined on D42, D63, and D84 (10, 31, and 52 days, respectively, after the end of the treatment). Values are means ± SD for 10 mice per group.
b
Organ weight/body weight.
c
[1 − (mean amastigote load in treated mice/mean amastigote load in NTC)] × 100. The parasite load data for the HDPC-treated and control mice are shown in Fig. 2.